ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2020
Therapy of Parkinson's Disease Subtypes.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Medical device-based neuromodulation for motor symptoms in Parkinson's disease: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Review
- Beyond nigrostriatal dopamine transporter loss: whole-brain DAT depletion patterns discriminate PD phenotypes.European journal of nuclear medicine and molecular imaging · 2026Article
- Behavioral screening defines the molecular Parkinsonism-related subgroups in Drosophila.Nature communications · 2026Article
- Drumming with BEAT: a pilot study on the impact of drum set playing on motor control and quality of life in Parkinson's disease.Frontiers in rehabilitation sciences · 2026Article
- Overcoming the diagnostic gap in mild cognitive impairment in Parkinson's disease: a pilot study employing a machine learning-/augmented reality-based digital biomarker.Frontiers in aging neuroscience · 2026Article
- Comparison of automated white matter lesion segmentation approaches for use in large, multi-site data analyses in Parkinson's disease.Frontiers in neuroscience · 2026Article
- Multidimensional Characterization of Parkinson's Disease Subtypes Through Motor Neuron Excitability and Peripheral Immune Dynamics: Insights from F-Wave Modulation Metrics.Diagnostics (Basel, Switzerland) · 2025Article
- Identifying the biomarkers associated with G protein-coupled receptors of parkinson's disease.Scientific reports · 2025Article
- An international 20 country patient and physician survey of the usability and acceptability of Stepped Care pathway in Parkinson's disease.Scientific reports · 2025Article
- Article
- Burden of tremor in Parkinson's disease: A survey study.Journal of Parkinson's disease · 2025Article
- Identifying genetic targets in clinical subtypes of Parkinson's disease for optimizing pharmacological treatment strategies.Signal transduction and targeted therapy · 2024Article
- MRI subtypes in Parkinson's disease across diverse populations and clustering approaches.NPJ Parkinson's disease · 2024Article
- Replication and reliability of Parkinson's disease clinical subtypes.Parkinsonism & related disorders · 2024Article
- Article
- Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.Current neuropharmacology · 2024Review
- Addressing Comorbidities in People with Parkinson's Disease: Considerations From An Expert Panel.Journal of Parkinson's disease · 2024Review
- Simulating combined monoaminergic depletions in a PD animal model through a bio-constrained differential equations system.Frontiers in computational neuroscience · 2024Article
- Microstructural alterations in white matter and related neurobiology based on the new clinical subtypes of Parkinson's disease.Frontiers in neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early descriptions of subtypes of Parkinson's disease (PD) are dominated by the approach of predetermined groups. Experts defined, from clinical observation, groups based on clinical or demographic features that appeared to divide PD into clinically distinct subsets. Common bases on which to define subtypes have been motor phenotype (tremor dominant vs akinetic-rigid or postural instability gait disorder types), age, nonmotor dominant symptoms, and genetic forms. Recently, data-driven approaches have been used to define PD subtypes, taking an unbiased statistical approach to the identification of PD subgroups. The vast majority of data-driven subtyping has been done based on clinical features. Biomarker-based subtyping is an emerging but still quite undeveloped field. Not all of the subtyping methods have established therapeutic implications. This may not be surprising given that they were born largely from clinical observations of phenotype and not in observations regarding treatment response or biological hypotheses. The next frontier for subtypes research as it applies to personalized medicine in PD is the development of genotype-specific therapies. Therapies for GBA-PD and LRRK2-PD are already under development. This review discusses each of the major subtyping systems/methods in terms of its applicability to therapy in PD, and the opportunities and challenges designing clinical trials to develop the evidence base for personalized medicine based on subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.